CoChat

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019

Open access
Garbe, Claus, Amaral, Teresa, Peris, Ketty, Hauschild, Axel, Arenberger, Petr, Bastholt, Lars, Bataille, Veronique, del Marmol, Veronique, Dréno, Brigitte, Fargnoli, Maria Concetta, Grob, Jean-Jacques, Höller, Christoph, Kaufmann, Roland, Lallas, Aimilios, Lebbé, Celeste, Malvehy, Josep, Middleton, Mark, Moreno-Ramirez, David, Pellacani, Giovanni, Saiag, Philippe, Stratigos, Alexander J., Vieira, Ricardo, Zalaudek, Iris, Eggermont, Alexander M.M. · 2020 · European Journal of Cancer
Cited by 192

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumor and causes 90% of skin cancer mortality. A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts' experience. The diagnosis of melanoma can be made clinically and shall always be confirmed through dermatoscopy. If a melanoma is suspected, a histopathological examination is required. Sequential digital dermatoscopy and full-body photography can be used in risk persons to detect the development of melanomas at an earlier stage. Where available, confocal reflectance microscopy can improve clinical diagnosis in special cases. Melanoma shall be classified according to the 8th version of the AJCC classification. Thin melanomas up to 0.8 mm tumor thickness does not require further imaging diagnostics. From stage IB onwards, examinations with lymph node sonography are recommended, but no further imaging examinations. From stage IIC whole-body examinations with CT or PET-CT in combination with brain MRI are recommended. From stage III and higher, mutation testing is recommended, particularly for BRAF V600 mutation. It is important to provide a structured follow-up to detect relapses and secondary primary melanomas as early as possible. There is no evidence to support the frequency and extent of examinations. A stage-based follow-up scheme is proposed, which, according to the experience of the guideline group, covers the minimum requirements; further studies may be considered. This guideline is valid until the end of 2021.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2019.11.014

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Metadata

Authors
Garbe, C., Amaral, T., Peris, K., Hauschild, A., Arenberger, P., Bastholt, L., Bataille, V., del Marmol, V., Dréno, B., Fargnoli, M. C., Grob, J.-J., Höller, C., Kaufmann, R., Lallas, A., Lebbé, C., Malvehy, J., Middleton, M., Moreno-Ramirez, D., Pellacani, G., Saiag, P., Stratigos, A. J., Vieira, R., Zalaudek, I., & Eggermont, A. M. M.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2020-02
Volume
126
Pages
141-158
ISSN
0959-8049 (ISSN-L)
OpenAlex
W3000052733
Cited by
192
References
6
FWCI
11.31
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.